查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138386

全球套細胞淋巴瘤市場-2022-2029

Global Mantle Cell Lymphoma Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

主要驅動因素是套細胞淋巴瘤的患病率不斷提高，以及由於醫療保健行業的研發活動增加而不斷增長的產品線。

正在進行的研發活動預計將推動市場增長。

一個有前途的套細胞淋巴瘤管道將在預測期內推動市場增長。例如，阿斯利康 (AstraZeneca) 正在讚助一項針對用這種新型藥物治療的套細胞淋巴瘤患者的前瞻性疾病登記，預計將於 2024 年 3 月 20 日完成。由首爾國立大學醫院贊助的一項 2 期研究，旨在評估硼替佐米、阿糖胞甘和地塞米鬆對復發或難治性套細胞淋巴瘤患者的療效，計劃於 2025 年 6 月開始，復發並由 Precog 贊助 - 一項 I/II 期試驗ixazomib和ibrutinib治療難治性套細胞淋巴瘤等。此外，與武田聯合開展的ixazomib維持治療新診斷套細胞淋巴瘤患者的多中心II期研究預計將於2024年12月完成（Kosin大學福音醫院，武田製藥贊助，預計上市時間：12月2022）計劃於2022年完成。

高昂的開發成本和副作用的出現預計將阻礙全球套細胞淋巴瘤市場的增長。

然而，貧血、中性粒細胞減少和腹瀉等嚴重的藥物副作用正在抑制市場增長。

行業分析。

全球套細胞淋巴瘤市場報告根據波特五力、創新、新產品發布、定價分析和管道分析等各種行業因素對市場進行了深入分析。

COVID-19 影響分析

COVID-19 對全球套細胞淋巴瘤市場產生了重大影響。由於 COVID-19 遏制協議，許多市場參與者的供應鏈被打亂，導致原材料短缺並擾亂供應鏈。此外，由於社會化規定，定期健康檢查困難，大部分□□套細胞淋巴瘤患者未被發現，這對大流行期間全球套細胞淋巴瘤市場的增長產生了負面影響。

套細胞淋巴瘤全球市場報告將提供對大約 40 多個市場數據表、45 多個圖表和 200 多頁（大約）的訪問。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 研發
      • 癌症患者增加
    • 限制因素
      • 開發成本高
      • 副作用
    • 商機
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按治療類型

  • 靶向治療
  • 化療
  • 放射治療
  • 其他

第 8 章給藥途徑

  • 口語
  • 注入

第 9 章，最終用戶

  • 醫院和診所
  • 癌症研究中心
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 12 章公司簡介

  • Kite Pharma, Inc.（Gilead Sciences, Inc.）
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • F. Hoffman La Roche Ltd
  • Abbvie, Inc.
  • Celgene Corporation
  • Eli Lilly and Company
  • Amgen, Inc.
  • Takeda Pharmaceutical Co. Ltd
  • AstraZeneca Plc
  • Johnson and Johnson

第13章 DataM

簡介目錄
Product Code: DMPH2172

Market Overview

Mantle Cell Lymphoma Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 7% during the forecast period (2022-2029).

Mantle cell lymphoma (MCL) is a rare type of blood cancer due to the excessive growth of lymphocytes. Mantle cell lymphoma (MCL) is one of the B-cell non-Hodgkin lymphomas, which occur due to the formation of tumors in the lymph nodes, which enter the blood and spread to the bone marrow, spleen, digestive tract, and liver.

Market Dynamics

The major driving forces are the growing prevalence of mantle cell lymphoma and increasing research & development activities in the healthcare sector resulting in a robust product pipeline.

The presence of ongoing research and development activities is expected to drive market growth.

The promising mantle cell lymphoma pipeline will drive market growth over the forecast period. For instance, AstraZeneca has sponsored a prospective disease registry of patients with mantle cell lymphoma treated with novel agents and is anticipated to be completed on March 20, 2024; a Phase 2 trial to assess the efficacy of bortezomib, cytarabine, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma, sponsored by Seoul National University Hospital and is anticipated to be launched in June 2025, a Phase I/II study of ixazomib and ibrutinib in relapsed/refractory mantle cell lymphoma sponsored by PrECOG, LLC. In collaboration with Takeda and anticipated to be completed in December 2024 and a Multicenter Phase II study of ixazomib maintenance in patients with newly diagnosed mantle cell lymphoma, Kosin University Gospel Hospital, in collaboration with Takeda sponsored and expected launch is in December 2022.

The high development cost and the onset of side effects are expected to hinder global mantle cell lymphoma market growth.

However, serious side effects of drugs like anemia, neutropenia, and diarrhea are restraining market growth.

Industry analysis.

The global mantle cell lymphoma market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing analysis, and pipeline analysis.

COVID-19 Impact Analysis

COVID-19 has significantly impacted the global mantle cell lymphoma market. Because of the COVID-19 containment protocols, the supply chain of many market players was disrupted and caused a lack of raw materials, which disturbed the supply and demand chain. Furthermore, due to the socializing restrictions, regular healthcare checkups were difficult, leaving most patients with mantle cell lymphoma undetected, negatively impacting the global mantle cell lymphoma market growth during the pandemic.

Segment Analysis

The targeted therapy segment is assumed to command the Mantle Cell Lymphoma market throughout the forecast period (2022-2029).

The targeted therapy segment is expected to grow rapidly over the forecast period (2022-2029). Developing targeted agents with low toxicity profiles for treating relapsed mantle cell lymphoma (MCL) in combination with approved drugs is a major factor in augmenting the mantle cell lymphoma treatment market growth. The introduction of the novel targeted agent's ibrutinib (Imbruvica), acalabrutinib (Calquence), and venetoclax (Venclexta), among others, is rapidly changing the relapsed/refractory space of the mantle cell lymphoma (MCL) and the upfront setting of chronic lymphocytic leukemia (CLL), according to James N. Gerson, MD. For instance, a Phase II study of bendamustine and rituximab plus venetoclax in untreated mantle cell lymphoma over 60 years of age by PrECOG, LLC. In collaboration with Genentech, Inc., expected to be completed by March 2025 and a Pilot Study of acalabrutinib with bendamustine/rituximab followed by cytarabine/rituximab for untreated mantle cell lymphoma by Washington University School of Medicine in collaboration with Acerta Pharma BV estimated to be completed by November 2025.

Geographical Analysis

The North American region holds the largest market share of the global Mantle Cell Lymphoma market.

North America dominated the global mantle cell lymphoma market in 2021. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the presence of key market players in North America and their hold over the global market with increasing research and development activities. For instance, on July 24, 2020, a U.S.-based company, Kite, A Gilead Company. LLS secured the approval for its brexucabtagene autoleucel (formerly KTE-X19, now branded as Tecartus) as the first chimeric antigen receptor (CAR) T-cell therapy approved for patients with MCL. Furthermore, according to the rare disease organization, MCL usually occurs at 60 to 70 years old, and since the United States has a large pool of geriatric population is expected to dominate the global market. According to the U.S. Census Bureau estimation, over 54 million adults aged 65 and older in 2020 made up 16.5% of the total United States population, estimated to reach 85.7 million by 2050, accounting for 20% of the total United States Population.

Competitive Landscape

The major players operating in the global mantle cell lymphoma market are F. Hoffman La Roche Ltd, Abbvie, Inc., Kite Pharma, Inc. (Gilead Sciences, Inc.), Celgene Corporation, Eli Lilly and Company, Amgen, Inc., Takeda Pharmaceutical Co. Ltd, AstraZeneca Plc, and Johnson and Johnson. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the global growth of the mantle cell lymphoma market. For instance, on 16 August 2022, FDA accepted the supplemental Biologics License Application for Roche's Polivy combination for people with previously untreated diffuse large B-cell lymphoma. Also, on July 27, 2021, AbbVie and Calico announced the extension of collaboration focused on aging and age-related diseases.

Kite Pharma, Inc. (Gilead Sciences, Inc.)

Overview:

Kite Pharma is a branch of Gilead Sciences, Inc. Kite Pharma was established in 2009 with its headquarters in California, United States. Kite Pharma is a leading American biotechnology company involved in developing cancer immunotherapy products that are majorly focused on the genetically-engineered autologous T cell therapy with chimeric antigen receptors.

Product Portfolio:

The Kite Pharma, Inc. (Gilead Sciences, Inc.) product portfolio for mantle cell lymphoma contains Tecartus.

The global mantle cell lymphoma market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Research and Development
      • 4.1.1.2. Increasing Prevalence of Cancer Cases
    • 4.1.2. Restraints
      • 4.1.2.1. The High Development Cost
      • 4.1.2.2. Side Effects
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Therapy Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type Segment
    • 7.1.2. Market Attractiveness Index, By Therapy Type Segment
  • 7.2. Targeted Therapy
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Chemotherapy
  • 7.4. Radiotherapy
  • 7.5. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
    • 8.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 8.2. Oral
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Injectable

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals and Clinics
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Cancer Research Center
  • 9.4. Other

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Kite Pharma, Inc. (Gilead Sciences, Inc.)
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. F. Hoffman La Roche Ltd
  • 12.3. Abbvie, Inc.
  • 12.4. Celgene Corporation
  • 12.5. Eli Lilly and Company
  • 12.6. Amgen, Inc.
  • 12.7. Takeda Pharmaceutical Co. Ltd
  • 12.8. AstraZeneca Plc
  • 12.9. Johnson and Johnson

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us